Sept. 18, 2024 — Adare Pharma Solutions, a global contract development and manufacturing organization (CDMO) specializing in oral dosage forms, entered a strategic partnership with Laxxon Medical, a pharmaceutical technology company focused on advanced drug delivery solutions. The collaboration aims to leverage Adare’s state-of-the-art cGMP facilities and Laxxon’s innovative 3D printing technology to bring innovative new oral dosage forms to market.
 
The partnership will utilize the Screen-Printed Innovative Drug (SPID) Technology, licensed from Exentis Group, to create customizable, 3D-printed oral dosage forms with precise control over drug release profiles and improved bioavailability. The technology allows for the production of complex formulations with multiple active ingredients and tailored pharmacokinetics.

Read the full article on contractpharma.com

Share this page on social